Literature DB >> 23797984

Use of case-time-control design in pharmacovigilance applications: exploration with high-risk medications and unplanned hospital admissions in the Western Australian elderly.

Sylvie D Price1, C D'Arcy J Holman, Frank M Sanfilippo, Jon D Emery.   

Abstract

PURPOSE: To use a case-time-control design to derive preliminary estimates of unplanned hospitalisations attributable to suspected high-risk medications in elderly Western Australians.
METHODS: Using pharmaceutical claims linked to inpatient and other health records, the study applied a case-time-control design and conditional logistic regression to estimate odds ratios (ORs) for unplanned hospital admissions associated with anticoagulants, antirheumatics, opioids, corticosteroids and four major groups of cardiovascular drugs. Attributable fractions (AFs) were derived from the ORs to estimate the number and proportion of admissions associated with drug exposure. Results were compared with those obtained from a more conventional method using International Classification of Diseases (ICD) external cause codes to identify admissions related to adverse drug events.
RESULTS: The study involved 1 899 699 index hospital admissions. Six of the eight drug groups were associated with an increased risk of unplanned hospitalisation, opioids (adjusted OR = 1.81, 95%CI 1.75-1.88; AF = 44.9%) and corticosteroids (1.48, 1.42-1.54; 32.2%) linked with the highest risks. For all six, the estimated number of hospitalisations attributed to the medication in the exposed was higher (two to 31-fold) when derived from the case-time-control design compared with identification from ICD codes.
CONCLUSIONS: This study provides an alternative approach for identifying potentially harmful medications and suggests that the use of ICD external causes may underestimate adverse drug events. It takes drug exposure into account, can be applied to individual medications and may overcome under-reporting issues associated with conventional methods. The approach shows great potential as part of a post-marketing pharmacovigilance monitoring system in Australia and elsewhere.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  adverse drug events; australian elderly; case-time-control design; data linkage; hospitalisation; pharmaceutical claims; pharmacoepidemiology; pharmacovigilance

Mesh:

Year:  2013        PMID: 23797984     DOI: 10.1002/pds.3469

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  7 in total

1. 

Authors:  Eric I Benchimol; Liam Smeeth; Astrid Guttmann; Katie Harron; David Moher; Irene Petersen; Henrik T Sørensen; Jean-Marie Januel; Erik von Elm; Sinéad M Langan
Journal:  CMAJ       Date:  2019-02-25       Impact factor: 8.262

2.  Impact of specific Beers Criteria medications on associations between drug exposure and unplanned hospitalisation in elderly patients taking high-risk drugs: a case-time-control study in Western Australia.

Authors:  Sylvie D Price; C D'Arcy J Holman; Frank M Sanfilippo; Jon D Emery
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

3.  Long-term use and cost-effectiveness of secondary prevention drugs for heart disease in Western Australian seniors (WAMACH): a study protocol.

Authors:  Anthony S Gunnell; Matthew W Knuiman; Elizabeth Geelhoed; Michael S T Hobbs; Judith M Katzenellenbogen; Joseph Hung; Jamie M Rankin; Lee Nedkoff; Thomas G Briffa; Michael Ortiz; Malcolm Gillies; Anne Cordingley; Mitch Messer; Christian Gardner; Derrick Lopez; Emily Atkins; Qun Mai; Frank M Sanfilippo
Journal:  BMJ Open       Date:  2014-09-18       Impact factor: 2.692

4.  Potentially high-risk medication categories and unplanned hospitalizations: a case-time-control study.

Authors:  Chih-Wan Lin; Yu-Wen Wen; Liang-Kung Chen; Fei-Yuan Hsiao
Journal:  Sci Rep       Date:  2017-01-23       Impact factor: 4.379

5.  [The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement].

Authors:  Eric I Benchimol; Liam Smeeth; Astrid Guttmann; Katie Harron; Lars G Hemkens; David Moher; Irene Petersen; Henrik T Sørensen; Erik von Elm; Sinéad M Langan
Journal:  Z Evid Fortbild Qual Gesundhwes       Date:  2016-09-28

6.  The changing face of Australian data reforms: impact on pharmacoepidemiology research.

Authors:  Juliana de Oliveira Costa; Claudia Bruno; Andrea L Schaffer; Smriti Raichand; Emily A Karanges; Sallie-Anne Pearson
Journal:  Int J Popul Data Sci       Date:  2021-04-15

7.  The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement.

Authors:  Eric I Benchimol; Liam Smeeth; Astrid Guttmann; Katie Harron; David Moher; Irene Petersen; Henrik T Sørensen; Erik von Elm; Sinéad M Langan
Journal:  PLoS Med       Date:  2015-10-06       Impact factor: 11.069

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.